STAT+: Radiopharmaceutical shows promise in post-Pluvicto setting
Abivax's ulcerative colitis data, Fulcrum's scrapped sickle cell drug, and more biotech news from The Readout
Tag
Pharma
Live stream
RIVO news Listen to this section's headlines in an AI voice
Now:
Press play to start the stream
This browser does not support voice playback. Try Chrome, Edge or Safari.
STAT+: Pharmalittle: We’re reading about a Lilly threat to 340B hospitals, Ebola vaccine funding, and more
Lilly gave hospitals participating in a federal drug discount program five days to submit claims data or it will stop the price breaks
Biotech
STAT+: At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways
Here is some of what you may have missed from the world's largest cancer research meeting.
CDC is investigating a salmonella outbreak tied to moringa supplement capsules
Mogo Moringa LLC recalled 2 lots of its Pure Moringa Oleifera capsules on May 25 after 18 people across 14 states fell ill
Pharma
STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
Detailed study data for a pancreatic cancer treatment from Revolution Medicines confirmed it increased overall survival, from 13.2 months to 6.7 months
Biotech
STAT+: A turning point for pancreatic cancer patients
Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout
Business
STAT+: Medicare still won’t say how much covering obesity drugs will cost
Older adults on Medicare can get Wegovy and Zepbound for $50 a month, starting in July. But the agency still is not sharing how much this will cost taxpayers.
Biotech
STAT+: A standing ovation for RevMed, and caution for Akeso
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
Low-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.
Biotech
STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds
By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were encouraging.
Biotech
STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
Biotech
STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
Much-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.
Biotech
STAT+: China competition, ‘destruction’ at FDA give agency chance to restructure, Rick Pazdur says
Rick Pazdur on the FDA: “We've had a lot of destruction here, and it doesn't mean that we have to just go back and say, well, let's rebuild it as…
Biotech
STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
Biotech
STAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here. We’re ASCOmaxxing. Rest…
Biotech
STAT+: Allogene CEO David Chang stepping down
Pfizer invests billions to buy Chinese drugs, WHO maps experimental response to Ebola outbreak, and other biotech news from The Readout
Biotech
STAT+: Biotech veteran Jeremey Levin on why the industry’s future is secure, but American leadership is at risk
Biotech is producing scientific breakthroughs that once seemed impossible. But according to longtime industry executive Jeremy Levin, the institutions that support these advances, from regulators, to investors, and even public…
Business
STAT+: Trump’s pharma deals get tested
We still have a lot of questions about Trump's MFN deals with pharma companies.
Biotech
STAT+: Ahead of ASCO, all eyes on pancreatic cancer
Strong results from GSK's hepatitis B drug, engineered heart patches, and more biotech news from The Readout
Business News
CVS Caremark is reversing course on Eli Lilly’s weight loss drugs, adding both its shot and new pill to coverage
The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options
Business
STAT+: Trump’s drug-pricing deals set to be tested by new product launches
The public is about to get its first look at the prices of drugs launched since President Trump struck his most-favored-nation deals with 17 drugmakers.
Biotech
STAT+: Kailera’s own ‘triple-G’ drug also looks very powerful
The business of living forever, Chan Zuckerberg Biohub's AI protein model, and other biotech news from The Readout
Pharma
STAT+: Pharmalittle: We’re reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more
The FDA extended the decision deadline for an experimental breast cancer pill from AstraZeneca after an advisory panel voted against the drug
D.C. Diagnosis
STAT+: Praise for FDA’s acting commissioner
Kyle Diamantas doesn't have the typical CV for an FDA commissioner, but he's earning early praise.
Biotech
What do early data from Utah’s Doctronic AI pilot show?
In this edition of STAT Health Tech: Early data from a Utah pilot using AI to renew prescriptions, Oura files to go public, and more.
Biotech
STAT+: Five biotech news updates to stay on top of today
Eli Lilly spends more of its GLP-1 cash, Humira's masterclass in monopoly, and more updates from The Readout
Pharma
STAT+: Pharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
Eli Lilly reported that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a Phase 1 clinical trial
Pharma
STAT+: Eli Lilly to buy three small vaccine developers
Eli Lilly is acquiring three small vaccine developers, expanding its work in infectious diseases and giving the field a boost.
Business News
Eli Lilly is acquiring three vaccine startups as it makes a push into infectious disease
The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight loss drugs
First Opinion
Opinion: The innovation trap: How pharma weaponizes a word to extend monopolies
“Just because a company invests does not mean it has invented anything novel,” Tahir Amin and Rohit Malpani write in this excerpt from “Pharma Monopoly.”
A STAT Examination
STAT+: How Kyle Diamantas defied expectations as he rose to lead the FDA
WASHINGTON — People in the food world didn’t know what to expect when the Trump administration appointed a little-known Florida attorney as the FDA’s top food official in 2025. They…
Biotech
STAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study
Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.
Pharma
STAT+: Pharmalittle: We’re reading about a Parkinson’s drug setback, a Merck lung cancer therapy, and more
Biogen and Denali said their experimental Parkinson’s therapy failed to slow the degenerative brain disorder in a randomized trial
Biotech
STAT+: Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows
A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor progression by 65% in patients with lung cancer, according to Phase 3…
Biotech
STAT+: Immunovant shares surge on arthritis trial data
Trial results for Lilly's "triple-G" drug, FDA's leadership purge leaves chaos, and more biotech news from The Readout